

QIBA Communications Committee (QCC) Call

30 July 2021 at 11 AM CT

Draft Call Summary

Notes provided by Dr. Smith

In attendance

Anne M. Smith, PhD (Co-chair)

Alexander Guimaraes, MD, PhD

Ichiro Ikuta, MD, MMSc

Gudrun Zahlmann, PhD

RSNA

Joe Koudelik

Julie Lisiecki

Moderator: Dr. Smith

FDA approval of Aduhelm and PET Amyloid BC updates

- Dr. Guimaraes will send CMS request to Amyloid BC to give feedback re: reimbursement of the new Alzheimer's Disease drug that was approved by FDA (Aducanumab or Aduhelm).
- 1. Dr. Pepin: storyboard progress for MRE visibility (not available)
 - a. Also consider for an RSNA workshop (see below)
- 2. Dr. Guimaraes: update on MRI LinkedIn groups (none)
- 3. Dr. Guimaraes: update on identifying point/key people in cardiology domain
 - a. Making inroads in echo-cardiography
 - b. Hoping QIBA can play a role in new Profiles
- 4. Dr. Zahlmann: willingness to storyboard a possible research fellows' workshop
 - a. Once storyboard is mature enough, discuss with RSNA to help support/host workshop
 - b. Will look at EIBALL workshop, since they already had one
 - i. Targeted in Radiologists interested in Clinical Research
 - ii. How best to write a grant proposal for imaging biomarkers?
 - iii. Drafted a study design, and presented it
 - c. RSNA Clinical Trials Methodology Workshop is similar to above (6 days, with a finished product)
 - d. RSNA also offers day and weekend courses
 - i. Do something with RadSite – co-workshop, FDG PET/CT Solid Tumor
 - 1. Leaders of BC would explain the checklist and lessons learned
 - 2. Discuss a way forward for how to teach the conformance process to interested sites
 - 3. Look into the feasibility of offering CME credits
- 5. Dr. Guimaraes: update on quantitative CPT codes
 - a. Is there anything this group can do to support this effort?
 - b. How can we repeat the MRE success story for other biomarkers?

Next call: Friday, August 27th at 11 am CT (monthly, last Friday of the month)

This new committee intends to help promote QIBA and the value of quantitative imaging to clinical trials and clinical practice and the broader radiology community